Home » Posts tagged 'ind'
Tag Archives: ind
Andrew Hore – Quoted Micro 23 March 2020
Gin and spirits supplier British Honey Company (BHC) is using spare capacity in its distillery to produce # alcohol sanitisers. There is a shortage of sanitisers due to the coronavirus and HMRC has given permission for British Honey to produce denatured alcohol. The sanitisers are made with 70% alcohol and extracts of honey and green tea. Longer-term, the strategy is to buy other spirits brands to use spare capacity. British Honey started off as a honey producer and moved into craft spirits infused with honey in 2017. It has a computer-controlled, 1,000-litre capacity still and bottling facility with a capacity of 1.5 million bottles a year. Ingredients can be tracked. There has been £4m invested in this infrastructure. The existing products use a small proportion of this capacity. The company also produces spirits on behalf of third parties. Discussions have begun with some potential acquisitions. British Honey joined Aquis Stock Exchange at the beginning of the week and raised £4.25m (£3.88m after expenses) at 110p a share. Advanced assurance of eligibility for the Enterprise Investment Scheme has been obtained. The initial market capitalisation was £10m. Cairn is corporate adviser and Stanford Capital Partners is broker.
Sativa (SATI) is launching a cannabigerol (CBG) and alcohol-based hand sanitiser. CBG is thought to be effective as an antibacterial product and could combat superbugs.
Energy supplier Good Energy (GOOD) reported better than expected 2019 pre-tax profit. Underlying pre-tax profit still dipped from £2.3m to £2.1m due to lower gross margins. Profit is expected to bounce back to £3.1m in 2020. Both business and domestic customers were higher last year. The total dividend has been increased from 3.5p a share to 3.7p a share. Net debt was £39.2m at the end of 2019.
Brewer Shepherd Neame (SHEP) has decided not to pay the interim dividend of 6p a share announced the week before. The sharp downturn in trading and subsequent closure of pubs due to COVID-19 means that Shepherd Neame is also cutting capital investment and the board is taking a one-fifth cut in pay. Rent receipts from tenants were suspended from 16 March.
KR1 (KR1) has generated $168,000 from selling ATOM, taking the total raised from disposals to $290,000. It still holds nearly 17,000 ATOM.
Sheltered housing developer Walls and Futures REIT (WAFR) has outperformed its benchmark for a third year in a row. The MSCI UK Residential index increased by 4.4% in 2019, while Walls portfolio increased by 23%.
BWA Group (BWAP) says that its subsidiary has been awarded an exploration licence for an area known as Dehane in central Cameroon. The focus is rutile sands and other minerals. The permit is for three years and the financial commitment in year one is £275,000, followed by £207,000 in each of the next two years. Tri Castle Investments is subscribing £100,000 at 0.5p a share.
First Sentinel (FSEN) has raised £389,000 at 20p a share for working capital. VI Mining (VIM) raised £56,000 via a placing at 15p a share that was curtailed because of COVID-19. Further cash will be raised in the future.
Eastinco Mining and Exploration (EM.P) has secured a $200,000 facility from Augustin Corp, which is owned by a trust related to Eastinco executive chairman Charles Bray. The annual interest rate is 6 percentage points above commercial lending rates and the facility lasts for up to 18 months.
SAPO (SAPO) is holding a general meeting on 14 April to gain shareholder approval for increasing the share capital. Executive chairman Dr Keith Harris has been issued 20 million shares at 1p a share. The consideration will be paid by the end of 2024.
Belvedere Leisure Resorts (BELV) believes that once normality is resumed it can accelerate its resort development and deliver phase one on time.
Dozens Savings (DS07) says that 795 investors have subscribed for company bonds.
Trading in Dana International (DANA) shares remains suspended. The property investor is still trying to gain full information about share transfers.
Christian Taylor-Wilkinson has become interim chief executive of Altona Energy (ANR) following the resignation of executive chairman Qinfu Zhang.
AIM
Sales of COVID-19 tests by Novacyt (NCYT) continue to accelerate. It has received orders worth more than £8.7m in a six-week period. Manufacturing capacity is being increased.
Synairgen (SNG) is about to start a phase II trial for SNG001 for the treatment of an initial 100 patients with mild-moderate COVID-19. Initial results should be available by the summer. SNG001 is inhaled interferon beta, which has shown benefits in the treatment of SARS. The existing COPD phase II trial has been paused, but initial results suggest that there is clinical benefit.
Best of the Best (BOTB) would have been in trouble a decade ago when it generated its competition entries from airports and other areas of high footfall. Having gone online, the competitions organiser has continued to prosper. Additional marketing investment has helped the 2019-20 performance to be above expectations. The pre-tax profit forecast for the year to April 2020 has been raised from £2.6m to £3m.
Payment systems provider PCI-Pal (PCIP) has won a contract for its Agent Assist product with a UK government organisation. The annual contract value is £565,500.
Manx Financial (MFX) is buying back the 12.94% shareholding owned by Aaron Banks. Manx intends to pay £1.61m for the shares and then cancel them. This cash will become a loan to Manx and an existing £483,500 convertible will be added to the sum. Banks has requisitioned a general meeting at iodine manufacturer Iofina (IOF) in order to remove Lance Baller from the board and become a director himself. Banks does not intend to make a bid for the company.
Mobile payment services provider Bango (BGO) is still set to move into profit in 2020. End user spend doubled last year.
Indigovision (IND) is recommending a 405p a share cash bid from Motorola Solutions. This values the video security technology company at £30.4m. In 2019, pre-tax profit was $1.3m.
MJ Hudson (MJH) grew organic revenues by 12.5% in the first half. The asset management services provider has net cash of £20.1m following last year’s flotation. The acquisition of Meyler will expand the range of services provided in the US. The customer base is predominantly long-term and closed ended funds. A full year pre-tax profit of £1.1m is forecast.
Big Sofa Technologies (BST) has put itself up for sale and trading in the shares is suspended. The video and data analytics technology developer needs additional cash and it is difficult to raise funds in the market when there is so much uncertainty. The company expects proposals by the end of April.
The Wressle oil field development in north Lincolnshire is set to commence production in the second half of 2020 and Egdon Resources (EDG) has a 30% stake and is operator. Europa Oil and Gas (EOG) and Union Jack Oil (UJO) also have interests. The breakeven oil is estimated at $18/barrel. Production could start at 500 barrels a day. An application has been allowed against North Lincolnshire council for costs relating to delays in gaining a permit.
Diagnostic and precision testing services provider Diaceutics (DXRX) boosted revenues by 30% last year following its flotation. Although gross margins improved, a significant increase in headcount meant that pre-tax profit dipped to £500,000. The initial benefits of the investment in the business are showing through growth in Asia and other regions.
Regional property investor Real Estate investors (REI) increased its dividend by 7% to 3.8p a share. Like-for-like rental income was slightly lower at £16.9m and the weak retail property market led to a 3% reduction in EPRA NAV to 67.4p a share. Loan to value is 46.7%. The Midlands property market is strengthening ahead of the Commonwealth Games in Birmingham. An improvement in NAV to near-69p a share is forecast for 2020.
Xeros (XSG) has signed a joint development agreement with a global commercial laundry business. XFiltra micro-particle filtration technology will be included in the partner’s commercial washing machines. The EU plans to have micro-particle filtration in use by 2026. Xeros is likely to need to raise more cash next year.
Oncimmune (ONC) says NICE has completed a positive review of EarlyCDT Lung and believes that it can help in the early diagnosis of lung cancer.
MAIN MARKET
Trading in the shares of Boston International Holdings (BIH) has been suspended ahead of the proposed acquisition of invoice factoring company Alexanders Discount Ltd, which is based in the South East. Alexanders Discount accounts for the year to November 2019 are for a dormant company and the assets were worth £4. The standard list shell floated in October 2016.
Telecoms services provider Toople (TOOP) says that the integration of DMSL is ahead of plan and it has won two new contracts.
BATM Advanced Communications (BVC) is partnering with Novamed for an at-home COVID-19 diagnostic kit. The kit should be completed within four months.
AIQ Ltd (AIQ) has signed a conditional share purchase agreement for Alchemist Codes, a Malaysian IT services developer. AIQ is paying £2.3m in shares.
Andrew Hore
Will Italy Do A Trump
Italy this weekend, hold the future of the Euro in its hands. Sundays referendum will show whether Italy is prepared to do a Trump and turn its back on its political establishment, whilst at the same time shaking the EU to its foundations. Massive support for Beppe Grillo the Clown Prince of Italian politics and leader of the Five Star movement could lead to the collapse of Italian Banks and a Euro crisis of huge proportions. Italian voters appear to be in no mood for half measures.
They have had enough and they have smelt blood, as they continue to watch their country’s economy destroyed, blighted by the Euro and the intransigence of the Eurozones unelected bureaucrats. Sterling has been rocketing ahead over the last few weeks, much to the chagrin of the EUs bitter and disappointed leaders. Come Monday morning the political establishment not just of Italy but of the whole EU could have received the biggest shock of their political lives, rejection by a core EU member, home of The Treaty of Rome.
Berkeley Group Holdings BKG Produced a 33% rise in profit before tax for the half year to 31st October and is increasing its interim dividend by 11%. Earnings per share rose by 35.2% and net cash almost doubled to to £207.9m after dividends and share purchases. Because of increased stamp duty and economic uncertainty arising from the referendum reservations are down 20% on the same time last year. The Chairman disagrees and claims that market conditions are resilient and forward sales are strong enabling the company to announce a new 5 year target of at least £3billion profit before tax in the five years from 1st May 2016. The present 3 year target of £2 billion pounds over the 3 years to April 2018 is being met. Time alone will tell whether the chairman is correct or whether the company is being impacted by uncertainty and market volatility.
James Halstead JHD is finding trading conditions are challenging and it will be difficult for it to beat the figures for the previous year. Revenue has continued to be below that of last year with the best estimate being that the shortfall could be as large as 4-5%. In particular Halstead has suffered from a shortage of plasticiser, one of its main ingredients, after an explosion at one of BASF; European plants which has led to delays, shortages and rising prices.
IndigoVision Group IND is experiencing a substantial turn round in its second half with revenues up 20% on those of the first half. In addition overheads are materially below last years and the company is now trading profitably after the first half’s losses. The full year to the end of December is now expected to end profitably.
Villas & Houses For Sale In The Greek Islands – visit; http://www.hiddengreece.net
Daily Actions – UK Main & AIM markets 29022016
Daily Actions is a daily summary analysis of changes in short term actions from our Daily Recs – AIM and Daily Recs Main markets reports. This report is typically distributed before the open of trading in London.
AIM Market
ST Rec. changed | ||
From | To | |
Basic Resources | ||
Ariana Resources | Buy | Neutral |
Chaarat Gold Holdings | Neutral | Buy |
Asa Resource Group | Neutral | Buy |
Uru Metals | Neutral | Buy |
Regency Mines | Neutral | Buy |
Paternoster Resources | Buy | Neutral |
Financial Services | ||
IPM | Buy | Neutral |
Manx Financial | Neutral | Buy |
Dragon-Ukrainian Properties & Development | Buy | Neutral |
Fletcher King | Neutral | Buy |
Impax Asset Management Group | Neutral | Buy |
RAB Special Situations Company | Buy | Strong Buy |
Food & Beverage | ||
PureCircle | Buy | Neutral |
Health Care | ||
Abcam | Sell | Neutral |
Industrial Good & Services | ||
APC Technology Group | Neutral | Buy |
Nakama Group | Neutral | Buy |
The Kellan Group | Neutral | Buy |
Ironveld | Buy | Neutral |
Petards Group | Neutral | Buy |
Oil & Gas – Explorers | ||
Bowleven | Buy | Neutral |
Chariot Oil & Gas | Buy | Neutral |
Oil & Gas – Producers | ||
Frontera Resources | Buy | Neutral |
Technology | ||
Indigovision Group | Neutral | Buy |
Pennant International Group | Neutral | Buy |
Simigon | Neutral | Buy |
Telecommunications | ||
Alternative Networks | Buy | Neutral |
Main Market
ST Rec. changed | ||
From | To | |
Banks | ||
Royal Bank of Scotland | Neutral | Buy |
Engineering & Machinery | ||
Rotork | Buy | Neutral |
Food Producers & Processors | ||
Associated British Foods | Sell | Neutral |
General Retail | ||
Burberry Group | Buy | Neutral |
Health | ||
Smith & Nephew | Sell | Neutral |
Personal Care & Household Products | ||
McBride | Sell | Neutral |
Speciality & Other Finance | ||
London Stock Exchange Group | Neutral | Sell |
Support Services | ||
John Menzies | Neutral | Sell |
Michael Page International | Buy | Neutral |
Transport | ||
Easyjet | Neutral | Buy |
RISK WARNING
Intellisys Intelligent Analysis Limited (‘Intellisys’) does not make personal recommendations. The information in this publication is provided solely to enable you to make your own investment decisions. If you are unsure about dealing in shares and other equity investments, you must contact your financial adviser as these types of investments may not be suitable for everyone. The value of stocks and shares, and the income from them, can fall as well as rise and you may not get back the full amount you originally invested. If denominated in a foreign currency, fluctuations in the exchange rate will also affect the value of stocks and shares and the income from them. Past performance is not necessarily a guide to future performance. You agree to abide fully with Intellisys’ Term & Conditions, which are available to www.intellisys.uk.com
The full reports are available from Intellisys Intelligent Analysis website (www.intellisys.uk.com) by clicking on the ‘Research’ tab.
DISCLAIMER: Intellisys Intelligent Analysis Limited has prepared this report. Intellisys (“Intellisys”) is the trading name of Intellisys Intelligent Analysis Limited. Intellisys Intelligent Analysis Limited is a provider of financial research reports that indicate the possible value of quoted company shares. The information contained within any and all of Intellisys’ reports are designed to present an objective assessment of the possible value or relative value of a company and/or an actuarial sector or stock market index. Intellisys utilises as extensive as possible range of valuation tools and proprietary systems to derive its outputs. The base data for the models are derived from sources believed to be accurate but Intellisys Intelligent Analysis Limited does not warrant or guarantee the accuracy or reliability of the source data or its models and proprietary systems. Subscribers, and casual readers, should not rely upon the Intellisys’ research outputs when forming specific investment decisions but should seek advice specific to their situation and investment requirements from a person authorised under the Financial Services and Markets Act 2000, before entering into any investment agreement.Intellisys Intelligent Analysis Limited has used reasonable care and skill in compiling the content of this report. No representation or warranty, expressed or implied, is given by any person as to the accuracy or completeness or accuracy of the information and no responsibility or liability is accepted to the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise. In no event will Intellisys Intelligent Analysis Limited, Intellisys or any of its officers, employees or agents be liable to any other party for any direct, indirect, special or other consequential damages arising from the use of this report.
The Intellisys Intelligent Analysis Limited and/or Intellisys reports are not directed to any person in any jurisdiction where (by reason of that person’s nationality, residence or otherwise) the publication or availability of the Intellisys Intelligent Analysis Limited and/or Intellisys information may be prohibited. Persons in respect of whom such prohibitions apply must not access the Intellisys Intelligent Analysis Limited and/or Intellisys reports. Neither this document, nor any copy in whatever form of media, may be taken or transmitted into the United States, Canada, Australia, Ireland, South Africa or Japan or into any jurisdiction where it would be unlawful to do so. Any failure to comply with this restriction may constitute a violation of relevant local securities laws. Recipients of Intellisys Intelligent Analysis Limited and/or Intellisys reports outside the UK are not covered by the rules and regulations made for the protection of investors in the UK. Any user distributing information taken from any Intellisys Intelligent Analysis Limited or Intellisys report and/or the Intellisys website, in whatever form, to any other person, agrees to attach a copy of this Disclaimer and the Terms and Conditions of Use pages and obtain the agreement of such other person to comply with the terms set forth. Intellisys’ published reports are published for information purposes and only available to market counterparties, high net-worth and sophisticated individual investors. No Intellisys report constitutes an offer or invitation to trade, sell, purchase or acquire any shares or other financial instruments in any company or any interest therein, nor shall it form the basis of any contract entered into for the sale of shares or any other financial instrument in any company. Intellisys Intelligent Analysis Limited believes that the information within each and any of its reports to be correct, but its accuracy or completeness cannot be guaranteed. No representation or warranty, expressed or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or mis-statements, negligent or otherwise. Intellisys Intelligent Analysis Limited (including its Directors, employees and representatives) or a connected person may have positions in or options or other financial instruments on any of the securities mentioned within a report, and may buy, sell or offer to purchase or sell such securities from time to time, subject to restrictions imposed by internal rules. Subscribers, and casual reader, are reminded that the value of any financial instrument may go up or down and that past performance is not necessarily a guide to future performance. Intellisys Intelligent Analysis Limited is not registered with or regulated by any financial regulatory authority and does not offer, provide or purport to provide or offer investment advice. Intellisys Intelligent Analysis Limited can be contacted at Woodfield Cottage, The Street, Mortimer, Berkshire, United Kingdom RG7 3DW. |
Daily Actions – UK Main & AIM markets 22012016
Daily Actions is a daily summary analysis of changes in short term actions from our Daily Recs – AIM and Daily Recs Main markets reports. This report is typically distributed before the open of trading in London.
AIM Market
ST Rec. changed | ||
From | To | |
Basic Resources | ||
Condor Gold | Buy | Neutral |
James Cropper | Sell | Neutral |
Petropavlovsk | Neutral | Sell |
Serabi Gold | Neutral | Buy |
Financial Services | ||
Amphion Innovations | Neutral | Buy |
FastForward Innovations | Neutral | Buy |
LondonMetric Property | Buy | Neutral |
RAB Special Situations Company | Buy | Strong Buy |
Starvest | Buy | Neutral |
Food & Beverage | ||
Real Good Food Company | Buy | Neutral |
Health Care | ||
AorTech International | Buy | Neutral |
Eco Animal Health Group | Sell | Neutral |
Industrial Good & Services | ||
Gooch & Housego | Sell | Neutral |
Hydro International | Sell | Neutral |
Impellam Group | Sell | Neutral |
James Latham | Sell | Neutral |
Kennedy Ventures | Neutral | Buy |
NWF Group | Sell | Neutral |
Media | ||
Dods Group | Neutral | Buy |
Oil & Gas – Producers | ||
Victoria Oil & Gas | Strong Buy | Buy |
Technology | ||
Access Intelligence | Sell | Neutral |
Indigovision Group | Neutral | Buy |
Telecommunications | ||
Avanti Communications Group | Strong Buy | Buy |
Travel & Leisure | ||
Best of the Best | Sell | Neutral |
Main Market
ST Rec. changed | ||
From | To | |
Beverages | ||
SAB Miller | Sell | Neutral |
Engineering & Machinery | ||
Castings | Sell | Neutral |
Vesuvius | Buy | Neutral |
Hill & Smith | Sell | Neutral |
Vitec Group | Neutral | Buy |
Weir Group | Buy | Neutral |
Food Producers & Processors | ||
Cranswick | Sell | Neutral |
Insurance | ||
Jardine Lloyd Thompson | Neutral | Buy |
Leisure & Hotels | ||
Mitchells & Butlers | Buy | Neutral |
JD Wetherspoon | Buy | Neutral |
Media & Entertainment | ||
Informa | Neutral | Sell |
St. Ives | Sell | Neutral |
Personal Care & Household Products | ||
McBride | Sell | Neutral |
Reckitt Benckiser Group | Sell | Neutral |
Pharmaceuticals & Biotechnology | ||
BTG | Buy | Neutral |
Ixico | Buy | Neutral |
Real Estate – REIS | ||
CLS Holdings | Buy | Neutral |
J Smart | Sell | Neutral |
St. Modwen Properties | Buy | Neutral |
Speciality & Other Finance | ||
Aberdeen Asset Management | Buy | Neutral |
Support Services | ||
Aggreko | Buy | Neutral |
AMEC Foster Wheeler | Buy | Neutral |
Compass Group | Sell | Neutral |
Berendsen | Sell | Neutral |
Michael Page International | Neutral | Buy |
Rexam | Sell | Neutral |
Utilities | ||
National Grid | Sell | Neutral |
Severn Trent | Sell | Neutral |
United Utilities Group | Sell | Neutral |
RISK WARNING
Intellisys Intelligent Analysis Limited (‘Intellisys’) does not make personal recommendations. The information in this publication is provided solely to enable you to make your own investment decisions. If you are unsure about dealing in shares and other equity investments, you must contact your financial adviser as these types of investments may not be suitable for everyone. The value of stocks and shares, and the income from them, can fall as well as rise and you may not get back the full amount you originally invested. If denominated in a foreign currency, fluctuations in the exchange rate will also affect the value of stocks and shares and the income from them. Past performance is not necessarily a guide to future performance. You agree to abide fully with Intellisys’ Term & Conditions, which are available to www.intellisys.uk.com
The full reports are available from Intellisys Intelligent Analysis website (www.intellisys.uk.com) by clicking on the ‘Research’ tab.
DISCLAIMER: Intellisys Intelligent Analysis Limited has prepared this report. Intellisys (“Intellisys”) is the trading name of Intellisys Intelligent Analysis Limited. Intellisys Intelligent Analysis Limited is a provider of financial research reports that indicate the possible value of quoted company shares. The information contained within any and all of Intellisys’ reports are designed to present an objective assessment of the possible value or relative value of a company and/or an actuarial sector or stock market index. Intellisys utilises as extensive as possible range of valuation tools and proprietary systems to derive its outputs. The base data for the models are derived from sources believed to be accurate but Intellisys Intelligent Analysis Limited does not warrant or guarantee the accuracy or reliability of the source data or its models and proprietary systems. Subscribers, and casual readers, should not rely upon the Intellisys’ research outputs when forming specific investment decisions but should seek advice specific to their situation and investment requirements from a person authorised under the Financial Services and Markets Act 2000, before entering into any investment agreement.Intellisys Intelligent Analysis Limited has used reasonable care and skill in compiling the content of this report. No representation or warranty, expressed or implied, is given by any person as to the accuracy or completeness or accuracy of the information and no responsibility or liability is accepted to the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise. In no event will Intellisys Intelligent Analysis Limited, Intellisys or any of its officers, employees or agents be liable to any other party for any direct, indirect, special or other consequential damages arising from the use of this report.The Intellisys Intelligent Analysis Limited and/or Intellisys reports are not directed to any person in any jurisdiction where (by reason of that person’s nationality, residence or otherwise) the publication or availability of the Intellisys Intelligent Analysis Limited and/or Intellisys information may be prohibited. Persons in respect of whom such prohibitions apply must not access the Intellisys Intelligent Analysis Limited and/or Intellisys reports. Neither this document, nor any copy in whatever form of media, may be taken or transmitted into the United States, Canada, Australia, Ireland, South Africa or Japan or into any jurisdiction where it would be unlawful to do so. Any failure to comply with this restriction may constitute a violation of relevant local securities laws. Recipients of Intellisys Intelligent Analysis Limited and/or Intellisys reports outside the UK are not covered by the rules and regulations made for the protection of investors in the UK.
Any user distributing information taken from any Intellisys Intelligent Analysis Limited or Intellisys report and/or the Intellisys website, in whatever form, to any other person, agrees to attach a copy of this Disclaimer and the Terms and Conditions of Use pages and obtain the agreement of such other person to comply with the terms set forth. Intellisys’ published reports are published for information purposes and only available to market counterparties, high net-worth and sophisticated individual investors. No Intellisys report constitutes an offer or invitation to trade, sell, purchase or acquire any shares or other financial instruments in any company or any interest therein, nor shall it form the basis of any contract entered into for the sale of shares or any other financial instrument in any company. Intellisys Intelligent Analysis Limited believes that the information within each and any of its reports to be correct, but its accuracy or completeness cannot be guaranteed. No representation or warranty, expressed or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or mis-statements, negligent or otherwise. Intellisys Intelligent Analysis Limited (including its Directors, employees and representatives) or a connected person may have positions in or options or other financial instruments on any of the securities mentioned within a report, and may buy, sell or offer to purchase or sell such securities from time to time, subject to restrictions imposed by internal rules. Subscribers, and casual reader, are reminded that the value of any financial instrument may go up or down and that past performance is not necessarily a guide to future performance. Intellisys Intelligent Analysis Limited is not registered with or regulated by any financial regulatory authority and does not offer, provide or purport to provide or offer investment advice. Intellisys Intelligent Analysis Limited can be contacted at Woodfield Cottage, The Street, Mortimer, Berkshire, United Kingdom RG7 3DW. |
Daily Actions – UK Main & AIM markets 19012016
Daily Actions is a daily summary analysis of changes in short term actions from our Daily Recs – AIM and Daily Recs Main markets reports. This report is typically distributed before the open of trading in London.
AIM Market
ST Rec. changed | ||
From | To | |
Basic Resources | ||
Amur Minerals Corporation | Neutral | Buy |
Avocet Mining | Sell | Neutral |
Metals Exploration | Neutral | Buy |
Patagonia Gold | Neutral | Buy |
Chemicals | ||
Plant Healthcare | Buy | Neutral |
Financial Services | ||
FastForward Innovations | Neutral | Buy |
Dragon-Ukrainian Properties & Development | Buy | Neutral |
LondonMetric Property | Neutral | Buy |
Raven Russia | Buy | Neutral |
Health Care | ||
AorTech International | Buy | Neutral |
Epistem Holdings | Neutral | Buy |
Industrial Good & Services | ||
Ceres Power Holdings | Buy | Neutral |
Impellam Group | Sell | Neutral |
MobilityOne | Buy | Neutral |
Oil & Gas – Explorers | ||
Ascent Resources | Neutral | Buy |
Oil & Gas – Producers | ||
Plexus Holdings | Neutral | Buy |
Technology | ||
Indigovision Group | Neutral | Buy |
Tern | Neutral | Buy |
Toumaz | Buy | Neutral |
Main Market
ST Rec. changed | ||
From | To | |
Banks | ||
HSBC | Neutral | Buy |
Heavy Construction | ||
Henry Boot | Sell | Neutral |
House Construction | ||
Bovis Homes Group | Neutral | Buy |
Electronics & Electrical Equipment | ||
Spectris | Neutral | Buy |
Engineering & Machinery | ||
Castings | Neutral | Sell |
Fenner | Buy | Neutral |
Hill & Smith | Sell | Neutral |
Morgan Advanced Material | Neutral | Buy |
Food Producers & Processors | ||
Cranswick | Sell | Neutral |
General Retail | ||
JD Sports Fashion | Sell | Neutral |
Health | ||
Bioquell | Neutral | Sell |
Household Goods & Textiles | ||
Headlam Group | Sell | Neutral |
Leisure & Hotels | ||
Mitchells & Butlers | Neutral | Buy |
Life Assurance | ||
Chesnara | Neutral | Sell |
Media & Entertainment | ||
Informa | Sell | Neutral |
St. Ives | Sell | Neutral |
Oil & Gas | ||
JKX Oil & Gas | Neutral | Sell |
Pharmaceuticals & Biotechnology | ||
Oxford Biomedica | Neutral | Buy |
Support Services | ||
Michael Page International | Neutral | Buy |
Rexam | Sell | Neutral |
Telecommunication Services | ||
BT Group | Sell | Neutral |
Utilities | ||
National Grid | Sell | Neutral |
RISK WARNING
Intellisys Intelligent Analysis Limited (‘Intellisys’) does not make personal recommendations. The information in this publication is provided solely to enable you to make your own investment decisions. If you are unsure about dealing in shares and other equity investments, you must contact your financial adviser as these types of investments may not be suitable for everyone. The value of stocks and shares, and the income from them, can fall as well as rise and you may not get back the full amount you originally invested. If denominated in a foreign currency, fluctuations in the exchange rate will also affect the value of stocks and shares and the income from them. Past performance is not necessarily a guide to future performance. You agree to abide fully with Intellisys’ Term & Conditions, which are available to www.intellisys.uk.com
The full reports are available from Intellisys Intelligent Analysis website (www.intellisys.uk.com) by clicking on the ‘Research’ tab.
DISCLAIMER: Intellisys Intelligent Analysis Limited has prepared this report. Intellisys (“Intellisys”) is the trading name of Intellisys Intelligent Analysis Limited. Intellisys Intelligent Analysis Limited is a provider of financial research reports that indicate the possible value of quoted company shares. The information contained within any and all of Intellisys’ reports are designed to present an objective assessment of the possible value or relative value of a company and/or an actuarial sector or stock market index. Intellisys utilises as extensive as possible range of valuation tools and proprietary systems to derive its outputs. The base data for the models are derived from sources believed to be accurate but Intellisys Intelligent Analysis Limited does not warrant or guarantee the accuracy or reliability of the source data or its models and proprietary systems. Subscribers, and casual readers, should not rely upon the Intellisys’ research outputs when forming specific investment decisions but should seek advice specific to their situation and investment requirements from a person authorised under the Financial Services and Markets Act 2000, before entering into any investment agreement.Intellisys Intelligent Analysis Limited has used reasonable care and skill in compiling the content of this report. No representation or warranty, expressed or implied, is given by any person as to the accuracy or completeness or accuracy of the information and no responsibility or liability is accepted to the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise. In no event will Intellisys Intelligent Analysis Limited, Intellisys or any of its officers, employees or agents be liable to any other party for any direct, indirect, special or other consequential damages arising from the use of this report.
The Intellisys Intelligent Analysis Limited and/or Intellisys reports are not directed to any person in any jurisdiction where (by reason of that person’s nationality, residence or otherwise) the publication or availability of the Intellisys Intelligent Analysis Limited and/or Intellisys information may be prohibited. Persons in respect of whom such prohibitions apply must not access the Intellisys Intelligent Analysis Limited and/or Intellisys reports. Neither this document, nor any copy in whatever form of media, may be taken or transmitted into the United States, Canada, Australia, Ireland, South Africa or Japan or into any jurisdiction where it would be unlawful to do so. Any failure to comply with this restriction may constitute a violation of relevant local securities laws. Recipients of Intellisys Intelligent Analysis Limited and/or Intellisys reports outside the UK are not covered by the rules and regulations made for the protection of investors in the UK. Any user distributing information taken from any Intellisys Intelligent Analysis Limited or Intellisys report and/or the Intellisys website, in whatever form, to any other person, agrees to attach a copy of this Disclaimer and the Terms and Conditions of Use pages and obtain the agreement of such other person to comply with the terms set forth. Intellisys’ published reports are published for information purposes and only available to market counterparties, high net-worth and sophisticated individual investors. No Intellisys report constitutes an offer or invitation to trade, sell, purchase or acquire any shares or other financial instruments in any company or any interest therein, nor shall it form the basis of any contract entered into for the sale of shares or any other financial instrument in any company. Intellisys Intelligent Analysis Limited believes that the information within each and any of its reports to be correct, but its accuracy or completeness cannot be guaranteed. No representation or warranty, expressed or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or mis-statements, negligent or otherwise. Intellisys Intelligent Analysis Limited (including its Directors, employees and representatives) or a connected person may have positions in or options or other financial instruments on any of the securities mentioned within a report, and may buy, sell or offer to purchase or sell such securities from time to time, subject to restrictions imposed by internal rules. Subscribers, and casual reader, are reminded that the value of any financial instrument may go up or down and that past performance is not necessarily a guide to future performance. Intellisys Intelligent Analysis Limited is not registered with or regulated by any financial regulatory authority and does not offer, provide or purport to provide or offer investment advice. Intellisys Intelligent Analysis Limited can be contacted at Woodfield Cottage, The Street, Mortimer, Berkshire, United Kingdom RG7 3DW. |
Quoted Micro 4 January 2016
ISDX
LED lighting supplier Gowin New Energy Group (GWIN) says that its former manufacturing partner Yichia Optoelectronics has ceased trading. Yichia has had financial difficulties for more than one year and Gowin has been outsourcing production to other companies in China. The agreement has been terminated. Because of the connection of the two companies via a variable interest entity structure Gowin was required to consolidate the results of Yichia. Gowin will write off the RMB10m of loans it made to Yichia. Two directors connected to Yichia have resigned from the Gowin board. Gowin says that its sales will decline in 2015 but the loss should be lower. Gowin believes it has enough working capital for 12 months. Trading in the shares was suspended on 27 November at 0.45p each because of the uncertainty about the business. Trading recommences on 4 January.
In May 2015, Angelfish Investments (ANGP) lent Andes Financial Services £250,000. This was originally repayable at the end of 2015 but it is now repayable in three tranches: £75,000 by the end of 2015 (already received), £75,000 by the end of January and £100,000 by the end of March. The annual interest rate on the outstanding balance continues to be 12%. If the loan is not paid it could be converted into shares in Andes, which is an FCA authorised investment business specialising in Latin America. Andes was formerly known as Latam Financial Services and Angelfish has a charge over its assets as security for the loan. Andes did not have any revenues in 2013 and 2014 and had potential tax losses of £93,000 at the end of 2014. Last September, nearly £10,000 was raised by Andes at 100p a share. The ultimate parent company of Andes is Apex Leader Investment Ltd. At 0.175p a share, Angelfish is valued at £1.2m.
Australia-based exploration company NQ Minerals (NQMI) has pegged drill holes ready for commencing drilling at Ukalunda in January. Metallurgy tests on samples from Ukalunda stockpiles have produced positive results. NQ has raised £100,000 from a placing at 8p a share. That was the original placing price but the share price has risen to 12.75p – the share price at which the most recent share deal was done. NQ is valued at £18.3m.
Employee-owned business-focused investment company Capital for Colleagues (CFCP) invested and lent an additional £685,000 in the three months to November 2015. The total invested and lent is £4.05m. At the end of November 2015, the NAV was 53.43p a share. The current share price is 60.5p.
Diversified Gas & Oil (DOIL) has raised an additional £960,000 from a further issue of 8.5% unsecured bonds 2020. This means that there are £4.17m of unsecured bonds in issue. The net proceeds are £912,000.
AIM
Video security systems supplier IndigoVision (IND) returned to profit in the second half of 2015, thanks to cost reductions, but it still made a full year loss. A Middle East contract was delayed. Revenues continue to decline but the rate of decline reduced from 29% in the first half to 18% in the second half. Net cash was more than $2m at the end of 2015, down from $2.56m one year earlier. The results will be announced on 3 March.
Online personal health company Fitbug Holding (FITB) admits that its loss increased in the second half because of changes in the US retail market. A new version of the Kiqplan health and fitness platform has been launched but the focus will be moved from retail to business to business customers, such as insurers. New chief executive Anna Gudmundson has appointed new management. Just before the end of the year £650,000 was raised via a loan from NW1 Investments. The loan lasts until July 2017. Discussions are ongoing with Fitbit Inc regarding litigation.
MAIN MARKET
Standard list cash shell Silver Falcon (SILF) has entered into a non-binding agreement that could lead to the acquisition of Lime Holdings Ltd, which has developed a platform for the automated delivery of insurance to customers. The deal will be a share for share exchange. Lime has been based in Australia but it recently moved its headquarters to the UK. Trading in the shares was suspended before Christmas at 3.75p each. Silver Falcon has limited cash balances so it may need to raise additional working capital if the acquisition goes through.
China-focused healthcare investor Cathay International Holdings (CTI) expects expenses to be much higher than anticipated due to higher marketing costs. There will be a significant loss before tax in 2015, although revenues have been in line with expectations despite tough markets in China. There have also been problems at 50.6% owned Lansen Pharmaceutical. Batches of Gingko did not meet regulatory standards and a penalty of $2.74m has been levied by the authorities.
Passenger aircraft lessor Avation (AVAP) has acquired and delivered a third ATR 72-600 aircraft to Flybe, which is using the aeroplane for an operational contract with Scandinavian Airlines and will fly in the latter’s livery. Avation expects to deliver a further four ATR 72-600 aircraft, which have a relatively low fuel consumption, in 2016. The standard list company has options over ATR 72 aircraft stretching out to 2023.
ANDREW HORE